RxDoctor Payments Data

Jessica Moyer, APRN

Psychiatric/Mental Health · Wellington, KSNPI 1790377695

Payments from drug & device makers

$1,527in general payments, 2019–2025

Across 56 payments — averaging $27.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$408
  • Teva Pharmaceuticals USA, Inc.$238
  • Johnson & Johnson$199
  • AbbVie$186
  • Supernus Pharmaceuticals, Inc.$158
  • Neuronetics, Inc.$78
  • plus $261 from 5 others

What the payments were for

  • Food & beverage$1,41893%
  • Education$1097%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,527 in reported general payments places this provider in the 70th percentile of 404 psychiatric/mental health providers in Kansas.

See all psychiatric/mental health providers in Kansas

Medicare billing

Part B allowed, 2024
$14,854
Medicare patients
52
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole55$82,476
Invega SustennaPaliperidone Palmitate13$52,488
VraylarCariprazine Hcl15$31,792
FanaptIloperidone18$23,974
Aripiprazole117$13,304
TrintellixVortioxetine Hydrobromide20$8,818
Divalproex Sodium ErDivalproex Sodium45$3,225
Olanzapine OdtOlanzapine21$2,998
Vilazodone Hcl30$2,986
Olanzapine104$2,777
Buspirone Hcl131$2,692
Lurasidone Hcl11$2,588
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$2,494
Quetiapine Fumarate ErQuetiapine Fumarate19$2,449
Venlafaxine Hcl ErVenlafaxine Hcl139$2,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$18$82,47655 claims
Johnson & JohnsonInvega Sustenna$199$52,48813 claims
AbbVieVraylar$186$31,79215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 404 psychiatric/mental health providers in Kansas.

Other psychiatric/mental health in Wellington

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →